INV-202

DRUG3 trials

Sponsors

Inversago Pharma Inc.

Conditions

Diabetic Kidney DiseaseMetabolic SyndromeObesity

Phase 1

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

CompletedNCT05282446

Inversago Pharma Inc.Metabolic Syndrome

Start: 2022-03-01End: 2022-10-01Updated: 2025-03-27

Phase 2

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

CompletedNCT05514548

Inversago Pharma Inc.Diabetic Kidney Disease

Start: 2022-10-19End: 2024-09-03Updated: 2025-08-11

Study of INV-202 in Patients With Obesity and Metabolic Syndrome

CompletedNCT05891834

Inversago Pharma Inc.Metabolic Syndrome, Obesity

Start: 2023-09-08End: 2025-02-14Updated: 2025-06-05

Related Papers

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.

2025-09-292 citations

431-P: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study

Diabetes2023-06-201 citations